Skip to main content

Table 1 Dose of SZU-101 and DOX in drug treatments

From: Local administration of a novel Toll-like receptor 7 agonist in combination with doxorubicin induces durable tumouricidal effects in a murine model of T cell lymphoma

Group

Final con. and dose of SZU-101

Final con. and dose of DOX

Injection i.t. (drug/PBS)

Injection i.p. (drug/PBS)

Ctrl

-

-

-/50 μl

-/100 μl

DOX

-

1.6 μg/μl; 4 mg/kg

50 μl/-

-/100 μl

SZU-101 i.t.

1.2 μg/μl; 3 mg/kg

-

50 μl/-

-/100 μl

SZU-101 i.p.

0.6 μg/μl; 3 mg/kg

-

-/50 μl

100 μl/-

CoAd i.t.

1.2 μg/μl; 3 mg/kg

1.6 μg/μl; 4 mg/kg

50 μl/-

-/100 μl

CoAd i.p.

0.6 μg/μl; 3 mg/kg

1.6 μg/μl; 4 mg/kg

50 μl/-

100 μl/-

  1. The combined administration was performed by injecting SZU-101 and DOX intratumourally (CoAd i.t.) or injecting DOX intratumourally, while injecting SZU-101 intraperitoneally (CoAd i.p.).